Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute oral cannabidiol for exercise tolerance in healthy trained runners
ACTRN12622000717752Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol (3 arms), sponsored by University of Sydney. Primary endpoint: Affective valence during submaximal running. Started Oct 2022; status: completed.
02
Drugs
cannabidiol
Beyond the preview
Go deeper on ACTRN12622000717752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000717752.